A hike in Amgen’s full-year guidance sent shares edging up in after-hours trading July 30, despite a 3 percent dip in revenues and an earnings miss for its second quarter. The Thousand Oaks biotech reported $5.87 billion in revenues for the quarter ended June 30, down from $6.06 billion in the previous second quarter, but…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
